Celldex falls on safety concern, even as chronic hives drug succeeds in Phase 3 trials
Celldex said its experimental treatment barzolvolimab hit its primary endpoint in two Phase 3 trials, even as the readout raised safety concerns.
Celldex Therapeutics
Celldex Therapeutics is a clinical-stage biotechnology company developing antibody-based therapies targeting inflammatory and allergic diseases. Recently scrapped its antibody for prurigo nodularis after a Phase 2 flop.
Company Info
Upcoming Milestones & Key Dates
Q4 2026
Strategic
Pipeline strategy update
Clinical Development Pipeline
CDX-1140
Target: CD40 agonistCDX-585
Target: Bispecific PD-1/TIM-3Undisclosed (CDX-6220)
Target: TBDRecent News
Celldex scraps antibody in itchy skin nodules after Phase 2 flop
Celldex scrapped its antibody for prurigo nodularis after a Phase 2 flop.
Leadership Team
Anthony Marucci
President, Chief Executive Officer and Co-Founder
Tibor Keler
Chief Scientific Officer and Co-Founder
To be confirmed
Chief Medical Officer